title: Higher disappearance rate of anti-HBs in Taiwanese freshers neonatally vaccinated with recombinant yeast hepatitis B vaccine.
abstract: The aim of this study was to compare the long-term efficacy of infant recombinant yeast hepatitis B vaccine (Recombinant group) and infant plasma-derived one (Plasma group) in Taiwanese freshers.
  
  
  
  Recruited were a total of 38 377 freshmen who underwent university entrance health examinations from 2003 to 2015. Subjects were assigned into two groups-plasma type and recombinant type, according to the national neonatal hepatitis B immunization program. The seroprevalences of hepatitis B surface antigen, antibody against hepatitis B surface antigen, and antibody against hepatitis B core antigen in each group and gender were calculated. Multivariate logistic regression analysis was performed to compare the efficacy of two groups.
  
  
  
  The HBsAg-positive rates in the plasma group and recombinant group were 1.5% and 0.3% respectively. The anti-HBs positive rates were 43.6% and 30.9%. The hepatitis B viral natural infection rates were 3.6% and 1.3%. Taking those who were born in July 1986-April 1992 as baseline group after adjustment for gender and age at hepatitis B markers checkup time, the efficacy of recombinant group in decreasing HBsAg positive rate, and decreasing hepatitis B virus natural infection rate was 71.0% (95% C.I.: 59.0-79.0%, P<.001) and 65.0% (95% C.I. 58.0-71.0%, P<.001) respectively. On the contrary, the seroprevalence of anti-HBs positive rate in recombinant group was 39.0% (95% C.I.: 36.0-42.0%, P<.001) lower than that of plasma group. (P<.001).
  
  
  
  Higher disappearance rate of anti-HBs was noted in recombinant group than in plasma group when the subjects reached their youth and young adulthood in Taiwan.
authors.affiliation: The Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Shu-Hua
authors.initials: SH
authors.lastname: Hsu
authors.affiliation: The School Health Center, National Taiwan University, Taipei, Taiwan.
authors.forename: An-Hsuan
authors.initials: AH
authors.lastname: Chih
authors.affiliation: The School Health Center, National Taiwan University, Taipei, Taiwan.
authors.forename: Yi-Chin
authors.initials: YC
authors.lastname: Lee
authors.affiliation: The Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.
authors.forename: Kuo-Chin
authors.initials: KC
authors.lastname: Huang
authors.affiliation: The Department of Family Medicine, National Taiwan University Hospital, Taipei, Taiwan.|The School Health Center, National Taiwan University, Taipei, Taiwan.
authors.forename: Chyi-Feng
authors.identifier: 0000-0003-2893-2187
authors.initials: CF
authors.lastname: Jan
mesh_terms: D000293:Adolescent; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D006511:Hepatitis B Antigens / Q000097:blood / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D012189:Retrospective Studies; D014611:Vaccination / Q000706:statistics & numerical data; D014614:Vaccines, Synthetic; D055815:Young Adult
chemical_list: D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic
keywords: efficacy; hepatitis B vaccine; young adults; youth